Wilmington, NC, 12 August 2020 – For the first time, Wilmington-headquartered Catalyst Clinical Research appears on the Inc. 5000 list of fastest-growing private companies in America. Catalyst ranked 1235 on the list.
Recognition on the Inc. 5000 list echoes unprecedented recent growth of the organization. Catalyst expanded from one North Carolina-based location to five locations with worldwide reach in the last three years. Over that period, the company added more than 120 jobs, experienced revenue growth of 365%, and is strongly positioned for continued growth with the recent merger with Ce3, Inc., a full-service CRO focused on providing early phase oncology clinical development and headquartered out of Clinton, Connecticut. Much of the company’s upward trajectory can be attributed to its growing customer base, expanding solutions, and continuation of its flexible, high-quality service delivery model.
“The companies on this year’s Inc. 5000 come from nearly every realm of business,” says Inc. editor-in-chief Scott Omelianuk. “From health and software to media and hospitality, the 2020 list proves that no matter the sector, incredible growth is based on the foundations of tenacity and opportunism.”
“The recognition by Inc. reflects the hard work and focus of the Catalyst team during a period of remarkable growth,” says Nick Dyer, Chief Executive Officer for Catalyst. “We owe a huge thanks to our loyal customers, trusted partners and dedicated team and look forward to continuing our commitment to deliver high quality services to the global biopharmaceutical market.”
Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at www.inc.com/inc5000.
Catalyst is a clinical development organization providing highly customizable clinical research solutions to the global biopharmaceutical industry. With offices in the US and EU, the company provides global resourcing solutions, functional and full-service managed solutions, the latter with a focus on oncology therapeutics. Catalyst’s service model is built from more than a decade of listening to customers, devising customer-centric solutions and helping them drive breakthrough clinical development studies leveraging Catalyst’s expert teams and innovative technologies.
Catalyst is a portfolio company of NovaQuest Capital Management, LLC, a leading healthcare and life sciences investment firm.
Ce3, Inc. is a full-service CRO focused on providing early phase oncology clinical development services to the biotechnology industry. The company’s therapeutic concentration is oncology, with a focus on novel modalities including immuno-oncology, cell and gene therapies. Since its inception in 2005, Ce3 has concentrated on thoroughly understanding the needs of biotechnology companies while providing high-quality, cost-effective solutions to support their clients’ analytical, regulatory, and investor goals. Ce3 merged with Catalyst Clinical Research in August 2020 to form a next-generation market-leading oncology CRO.